New York State Common Retirement Fund Has $506,000 Stake in Karyopharm Therapeutics Inc (KPTI)

Share on StockTwits

New York State Common Retirement Fund lifted its stake in Karyopharm Therapeutics Inc (NASDAQ:KPTI) by 23.6% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,700 shares of the company’s stock after purchasing an additional 7,200 shares during the period. New York State Common Retirement Fund owned 0.08% of Karyopharm Therapeutics worth $506,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Wells Fargo & Company MN increased its stake in shares of Karyopharm Therapeutics by 18.8% in the 4th quarter. Wells Fargo & Company MN now owns 30,974 shares of the company’s stock worth $298,000 after purchasing an additional 4,902 shares in the last quarter. Swiss National Bank increased its stake in shares of Karyopharm Therapeutics by 12.8% in the 1st quarter. Swiss National Bank now owns 64,150 shares of the company’s stock worth $861,000 after purchasing an additional 7,300 shares in the last quarter. Schwab Charles Investment Management Inc. increased its stake in shares of Karyopharm Therapeutics by 7.1% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 150,289 shares of the company’s stock worth $1,443,000 after purchasing an additional 9,929 shares in the last quarter. Two Sigma Investments LP increased its stake in shares of Karyopharm Therapeutics by 76.8% in the 4th quarter. Two Sigma Investments LP now owns 24,220 shares of the company’s stock worth $233,000 after purchasing an additional 10,520 shares in the last quarter. Finally, Northern Trust Corp increased its stake in shares of Karyopharm Therapeutics by 3.0% in the 1st quarter. Northern Trust Corp now owns 397,294 shares of the company’s stock worth $5,331,000 after purchasing an additional 11,577 shares in the last quarter. Hedge funds and other institutional investors own 61.90% of the company’s stock.

In other Karyopharm Therapeutics news, insider Sharon Shacham sold 10,000 shares of the stock in a transaction dated Monday, June 18th. The shares were sold at an average price of $18.66, for a total transaction of $186,600.00. Following the completion of the transaction, the insider now owns 713,510 shares of the company’s stock, valued at approximately $13,314,096.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Christopher Brett Primiano sold 2,000 shares of the stock in a transaction dated Thursday, May 10th. The shares were sold at an average price of $18.01, for a total transaction of $36,020.00. Following the transaction, the executive vice president now directly owns 675 shares of the company’s stock, valued at approximately $12,156.75. The disclosure for this sale can be found here. Insiders sold a total of 62,000 shares of company stock valued at $1,029,920 in the last quarter. 13.26% of the stock is currently owned by company insiders.

KPTI has been the subject of several analyst reports. Cantor Fitzgerald set a $18.00 price objective on Karyopharm Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, March 21st. BidaskClub lowered Karyopharm Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, March 20th. Robert W. Baird set a $22.00 price objective on Karyopharm Therapeutics and gave the stock a “buy” rating in a research note on Thursday, March 15th. HC Wainwright upped their price objective on Karyopharm Therapeutics to $26.00 and gave the stock a “buy” rating in a research note on Thursday, March 15th. Finally, Canaccord Genuity upped their price objective on Karyopharm Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a research note on Monday, March 12th. Two investment analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $20.91.

Shares of KPTI stock opened at $17.89 on Wednesday. Karyopharm Therapeutics Inc has a 52-week low of $8.00 and a 52-week high of $20.39. The firm has a market capitalization of $846.95 million, a price-to-earnings ratio of -6.37 and a beta of 3.75.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Thursday, May 10th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.11). The business had revenue of $10.00 million during the quarter, compared to analyst estimates of $4.59 million. equities analysts expect that Karyopharm Therapeutics Inc will post -3.08 earnings per share for the current fiscal year.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.

Want to see what other hedge funds are holding KPTI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Karyopharm Therapeutics Inc (NASDAQ:KPTI).

Institutional Ownership by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply